JP2025504815A5 - - Google Patents
Info
- Publication number
- JP2025504815A5 JP2025504815A5 JP2024541851A JP2024541851A JP2025504815A5 JP 2025504815 A5 JP2025504815 A5 JP 2025504815A5 JP 2024541851 A JP2024541851 A JP 2024541851A JP 2024541851 A JP2024541851 A JP 2024541851A JP 2025504815 A5 JP2025504815 A5 JP 2025504815A5
- Authority
- JP
- Japan
- Prior art keywords
- fcrn antagonist
- subject
- cells
- once
- frequency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266852P | 2022-01-17 | 2022-01-17 | |
| US63/266,852 | 2022-01-17 | ||
| PCT/EP2023/050980 WO2023135321A1 (en) | 2022-01-17 | 2023-01-17 | Methods for treating patients with an autoantibody-mediated disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504815A JP2025504815A (ja) | 2025-02-19 |
| JP2025504815A5 true JP2025504815A5 (https=) | 2026-01-26 |
Family
ID=85036487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541851A Pending JP2025504815A (ja) | 2022-01-17 | 2023-01-17 | 自己抗体媒介性疾患を有する患者を治療するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240369467A1 (https=) |
| EP (1) | EP4466539A1 (https=) |
| JP (1) | JP2025504815A (https=) |
| KR (1) | KR20240134900A (https=) |
| CN (1) | CN118556187A (https=) |
| AR (1) | AR128284A1 (https=) |
| AU (1) | AU2023207461A1 (https=) |
| CA (1) | CA3241453A1 (https=) |
| IL (1) | IL314322A (https=) |
| MX (1) | MX2024007806A (https=) |
| TW (1) | TW202333791A (https=) |
| WO (1) | WO2023135321A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| TW202421195A (zh) * | 2022-11-07 | 2024-06-01 | 比利時商阿根思公司 | 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法 |
| WO2025093717A1 (en) * | 2023-10-31 | 2025-05-08 | Immunovant Sciences Gmbh | Methods of improving anti-fcrn therapies |
| WO2025202714A1 (en) * | 2024-03-26 | 2025-10-02 | argenx BV | Methods for treating primary sjogren's syndrome using fcrn antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| JP2023509195A (ja) * | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
-
2023
- 2023-01-17 KR KR1020247023836A patent/KR20240134900A/ko active Pending
- 2023-01-17 CA CA3241453A patent/CA3241453A1/en active Pending
- 2023-01-17 MX MX2024007806A patent/MX2024007806A/es unknown
- 2023-01-17 JP JP2024541851A patent/JP2025504815A/ja active Pending
- 2023-01-17 AR ARP230100108A patent/AR128284A1/es unknown
- 2023-01-17 AU AU2023207461A patent/AU2023207461A1/en active Pending
- 2023-01-17 EP EP23701274.5A patent/EP4466539A1/en active Pending
- 2023-01-17 IL IL314322A patent/IL314322A/en unknown
- 2023-01-17 TW TW112102126A patent/TW202333791A/zh unknown
- 2023-01-17 CN CN202380017265.XA patent/CN118556187A/zh active Pending
- 2023-01-17 WO PCT/EP2023/050980 patent/WO2023135321A1/en not_active Ceased
-
2024
- 2024-07-16 US US18/774,570 patent/US20240369467A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025504815A5 (https=) | ||
| JP2018509413A5 (https=) | ||
| AU2019244478B2 (en) | Subcutaneous dosing of anti-CD38 antibodies | |
| JP2017501725A5 (https=) | ||
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| JP2024530152A5 (https=) | ||
| JP2018531591A5 (https=) | ||
| CN103946238B (zh) | 抗ox40抗体及使用其的方法 | |
| JP2025000867A5 (https=) | ||
| AU2013206788B2 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| JP2016527187A5 (https=) | ||
| JP2021506786A5 (https=) | ||
| JP2018528258A5 (https=) | ||
| CN109134652B (zh) | Pan-ELR+ CXC趋化因子抗体 | |
| GB2644460A (en) | TCR targeting molecules and uses thereof | |
| JP2025520420A5 (https=) | ||
| TW202333791A (zh) | 用於治療患有自體抗體介導之疾病之患者的方法 | |
| JP2024504366A5 (https=) | ||
| US20250034230A1 (en) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof | |
| Buhrer et al. | Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Munster) Relapse Study Group | |
| JP2025508073A5 (https=) | ||
| NZ734416A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| US20180371075A1 (en) | Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3 | |
| NZ734416B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |